<DOC>
	<DOCNO>NCT01858935</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , pharmacokinetics ND-L02-s0201 normal , healthy , subject</brief_summary>
	<brief_title>A Phase 1 , Randomized , Double-Blind , Placebo-Controlled Escalating Single Dose Study Evaluate Safety , Tolerability Pharmacokinetics ND-L02-s0201 Injection Normal Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>1 . Male subject age 18 55 year . 2 . Willing able comply study procedure visit schedule , include followup visit . 3 . Able communicate effectively study site personnel . 4 . Body mass index ( BMI ) within range ≥18.5 ≤30 . 5 . Determined Investigator good health document follow : 1 . Medical history ; 2 . Physical examination ( include limit evaluation cardiovascular , gastrointestinal , respiratory central nervous system ) ; 3 . Vital sign assessment : systolic blood pressure ≤140 mmHg , diastolic blood pressure ≤90 mmHg , heart rate 4585 bpm ; 4 . Normal 12lead electrocardiogram ( ECG ) : heart rate : 4485 bpm , PR interval : ≤210 msec , QRS duration : ≤120 msec , QTcF : ≤430 msec ; 5 . Clinical laboratory assessment within laboratory 's limit normal value consider clinically significant Investigator ; 6 . By general observation . For abnormality deviation outside normal range clinical test ( include laboratory test , ECG , vital sign ) , test may repeat discretion Investigator , result must discuss Sponsor 's Medical Monitor judge clinically significant study participation . 6 . Serum calcium , parathyroid hormone , testosterone within laboratory 's limit normal value 25OHvitamin D ≥18 ng/mL . 7 . Nonsmoker , define smoking within 3 month prior administration study drug urine cotinine &lt; 400 ng/mL . 8 . Consumed average 2 drink per day within 6 month prior administration study drug . A drink one 12 oz . beer , 4 oz . wine , 1.5 oz . 80proof spirit , 1 oz . 100proof spirit . 9 . Subjects female partner childbearing potential must agree use effective barrier method contraception ( e.g. , condom spermicide ) study drug administration Day 28 visit . All fertile men female partner childbearing potential instruct contact Investigator immediately suspect partner might pregnant ( e.g. , miss late menstrual period ) time study participation . 10 . Subjects must give write informed consent . 1 . Any disease condition ( medical surgical ) , opinion Investigator , might compromise hematologic , cardiovascular , pulmonary , renal , gastrointestinal , hepatic , skeletal , central nervous system ; condition may interfere absorption , distribution , metabolism excretion NDL02s0201 , would place subject increase risk . 2 . History bone disease , include osteoporosis osteomalacia , Paget 's disease bone , history unexplained fracture fracture minimal trauma . 3 . The presence abnormal laboratory value consider clinically significant Investigator . 4 . Positive screen Hepatitis B ( HBsAg , Hepatitis B Surface Antigen ) , Hepatitis C ( antiHCV , Hepatitis C Antibody ) human immunodeficiency virus ( HIV ) ( antiHIV 1/2 ) . 5 . Participating concurrent interventional study last intervention occur within 30 day prior administration study drug . 6 . Received drug therapy ( include prescription overthecounter drug herbal supplement ) within 1 week 5 halflives ( whichever longer ) , prior administration study drug . Use nonsteroidal antiinflammatory drug ( NSAIDs ) , sulfonamide , probenecid drug know alter renal tubular function specifically prohibit least 5 halflives prior administration study drug . Use immunosuppressant specifically prohibit within 1 week 5 halflives ( whichever longer ) , prior administration study drug . Vitamin A containing multivitamin must withhold Day 1 Day 5 . 7 . Consumption alcohol within 48 hour prior administration study drug inpatient period . 8 . Positive urine screen drug abuse , include ethanol , cocaine , tetrahydrocannabinol ( THC ) , barbiturates , amphetamine , benzodiazepine , opiate , cotinine , drug abuse study site 's location . 9 . History , within last 2 year , alcohol abuse , significant mental illness , physical dependence opioid . 10 . Illicit drug use within last 90 day . 11 . Demonstration , opinion study staff , vein unsuitable repeated venipuncture intravenous infusion ( e.g. , vein difficult locate , access puncture ; vein tendency rupture puncture ) . 12 . Recent treatment alternative therapy , , opinion Investigator , could potentially confound clinical laboratory assessment . 13 . Donation loss 500 mL blood within 56 day prior administration study drug donation plasma within 7 day prior administration study drug . 14 . History malignancy within last 5 year , exception nonfacial basal cell carcinoma . 15 . History severe allergic anaphylactic reaction . 16 . Any reason , opinion Investigator Sponsor 's Medical Monitor , make subject unsuitable enrollment . 17 . History hypersensitivity H2receptor antagonist .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>